-

ICON Launches FIRECREST AI-Directed Video Engine, Changing the Economics of Site Communications

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the release of AI-directed video production capabilities within its FIRECREST site & patient communications platform.

ICON’s FIRECREST AI-directed video engine enables sponsors to automate the creation of high-quality, high-impact clinical trial videos. Unlike generic and unrestricted generative AI video tools, ICON’s FIRECREST empowers sponsors by delivering consistent, scalable and governed video output for regulated clinical trial environments, at speeds and scale that would previously have been prohibitively expensive.

The structured communication approach, templates, governance, and production methodology are predefined by ICON and sponsor subject matter experts, while AI executes and scales the production process.

Video production timelines are reduced approximately 10x, from days to hours. Sponsors maintain full control of production, review and launch processes, whilst all sponsor-confidential information is stored within ICON's secure environment.

With over half a million site users worldwide, and over five million clinical study related trainings delivered via the platform, FIRECREST creates a consistent operating model for site engagement across a Sponsor’s portfolio. The new AI-directed video engine leverages a rich library of proven content and templates, developed over more than 25 years of ICON’s experience creating study communications with its FIRECREST platform.

The platform's first application supports site selection and feasibility activities, converting study-specific information into engaging site selection videos that help investigator sites quickly understand research opportunities and study requirements.

“Clinical trials rely on effective communication with investigator sites,” said Brian Mallon, Executive Vice President, Site & Patient Solutions at ICON plc. “Video is a powerful communication format, and ICON’s AI-directed video engine removes cost and complexity, and is far faster than traditional video production, enabling sponsors to scale communication and deliver greater site engagement and message consistency, whilst maintaining governance and reducing risk”.

About ICON plc

ICON plc is a world-leading clinical research organisation. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialisation and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organisations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,200 employees in 99 locations in 55 countries as at June 30, 2026. For further information about ICON, visit: www.iconplc.com.

Contacts

Media contacts
Lisa Henry (GMT time zone)
Weber Shandwick (PR adviser)
+44 7785 458203
lisa.henry@omc.com

ICON Press Office
iconnews@omc.com

ICON plc

NASDAQ:ICLR

Release Versions

Contacts

Media contacts
Lisa Henry (GMT time zone)
Weber Shandwick (PR adviser)
+44 7785 458203
lisa.henry@omc.com

ICON Press Office
iconnews@omc.com

More News From ICON plc

ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced a multi-year collaboration with Anthropic to bring Claude’s AI capabilities across the clinical trial lifecycle. The collaboration further advances ICON’s digital innovation and AI strategy, and builds on Orbis – ICON’s secure, governed, agentic AI platform. Through this collaboration, ICON will work closely with Anthropic’s Life Sciences research team to explore and apply cutting-edge technologies that can accelerate innovation a...

ICON expands US early phase research capabilities with new clinic and outpatient centres

DUBLIN & SAN ANTONIO--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON’s capacity to conduct first-in-human, healthy participant, and patient cohort stu...

ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive

DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC)...
Back to Newsroom